TOP 10 - PULMÃO
  1. Início

Programação

Filtrar atividades
Auditório
08:35 - 08:40
Abertura

Abertura

Auditório
08:40 - 10:15
Palestra

Bloco 1

08:40 - 09:00
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer - NEJM - 2022
09:00 - 09:20
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial - Lancet 2022
09:20 - 09:40
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial) - JCO 2022
09:40 - 10:00
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial - Lancet 2021
10:00 - 10:15
Discussão do Bloco
Auditório
10:15 - 10:30
Intervalo

Coffee Break

Auditório
10:30 - 11:20
Palestra

Bloco 2

10:30 - 10:50
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial - Lancet Oncol 2022
10:50 - 11:10
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer - JCO – 2022
11:10 - 11:20
Discussão do Bloco
Auditório
11:20 - 12:50
Palestra

Bloco 3

11:20 - 11:40
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation – NEJM 2022
11:40 - 12:00
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study - JCO 2021
12:00 - 12:20
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A - JCO – 2022
12:20 - 12:40
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - Lancet Oncol 2022
12:40 - 12:50
Discussão do Bloco
Auditório
12:50 - 12:55
Encerramento

Encerramento

Auditório
12:55 - 13:00
Palestra

Conteúdo On Demand Novartis